Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment engages in the development, sale, and distribution of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1995 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:IPXL
CUSIP45256B10
Phone510-476-2000
Debt
Debt-to-Equity Ratio4.11
Current Ratio1.96
Quick Ratio1.52
Price-To-Earnings
Trailing P/E Ratio29.05
Forward P/E Ratio15.38
P/E Growth0.83
Sales & Book Value
Annual Sales$775.79 million
Price / Sales1.74
Cash Flow$2.0867 per share
Price / Cash8.77
Book Value$2.53 per share
Price / Book7.23
Profitability
EPS (Most Recent Fiscal Year)$0.63
Net Income$-469,280,000.00
Net Margins-60.49%
Return on Equity10.42%
Return on Assets2.83%
Miscellaneous
Employees1,257
Outstanding Shares73,870,000
Market Cap$1,351.85
Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions
What is Impax Laboratories' stock symbol?
Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."
How were Impax Laboratories' earnings last quarter?
Impax Laboratories (NASDAQ:IPXL) posted its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 60.49% and a positive return on equity of 10.42%. The company's revenue for the quarter was down 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.37 EPS. View Impax Laboratories' Earnings History.
What price target have analysts set for IPXL?
15 analysts have issued 12 month price objectives for Impax Laboratories' stock. Their forecasts range from $16.00 to $35.00. On average, they anticipate Impax Laboratories' stock price to reach $22.1333 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Ratings for Impax Laboratories.
What is the consensus analysts' recommendation for Impax Laboratories?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impax Laboratories in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Impax Laboratories stock?
Here are some recent quotes from research analysts about Impax Laboratories stock:
- 1. According to Zacks Investment Research, "Impax missed estimates for both the counts in the fourth quarter of 2017. The company faces competition in the brand product market from Parkinson’s disease and CNS disorder focused large pharmaceutical companies. Impax’s Generics segment underperformed in 2017, due to significant pricing erosion complemented by erosion in volume. However, the company’s epinephrine auto-injector sales have picked up. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. Shares of the company outperformed the industry in a year’s time." (3/27/2018)
- 2. Cantor Fitzgerald analysts commented, "IPXL announced this morning that Robert Stewart will be joining the company as CEO, effective January 25, 2018." (12/15/2017)
Who are some of Impax Laboratories' key competitors?
Some companies that are related to Impax Laboratories include Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY) and The Medicines (MDCO).
Who are Impax Laboratories' key executives?
Impax Laboratories' management team includes the folowing people:
- Mr. Bryan M. Reasons, Sr. VP of Fin. & CFO (Age 51)
- Mr. Mark A. Schlossberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
- Mr. Michael J. Nestor, Pres of Impax Specialty Pharma Division (Age 65)
- Mr. Douglas S. Boothe, Pres of Impax Generics Division (Age 54)
- Mr. Paul M. Bisaro, CEO, Pres & Director (Age 57)
Has Impax Laboratories been receiving favorable news coverage?
News articles about IPXL stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Impax Laboratories earned a coverage optimism score of 0.06 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 46.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Impax Laboratories?
Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Impax Laboratories' stock price today?
One share of IPXL stock can currently be purchased for approximately $18.30.
How big of a company is Impax Laboratories?
Impax Laboratories has a market capitalization of $1.35 billion and generates $775.79 million in revenue each year. The specialty pharmaceutical company earns $-469,280,000.00 in net income (profit) each year or $0.63 on an earnings per share basis. Impax Laboratories employs 1,257 workers across the globe.
How can I contact Impax Laboratories?
Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]
MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
